Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1983 1
1984 1
1985 3
1986 1
1987 1
1989 1
1990 2
1991 1
1995 1
1996 2
1997 3
1998 2
2000 3
2001 2
2002 2
2003 6
2005 5
2007 6
2008 1
2009 4
2010 7
2011 7
2012 6
2013 3
2014 12
2015 9
2016 10
2017 14
2018 5
2019 5
2020 7
2021 13
2022 13
2023 16
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

165 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, Koehler A, Sohn J, Iwata H, Telli ML, Ferrario C, Punie K, Penault-Llorca F, Patel S, Duc AN, Liste-Hermoso M, Maiya V, Molinero L, Chui SY, Harbeck N. Mittendorf EA, et al. Among authors: saji s. Lancet. 2020 Oct 10;396(10257):1090-1100. doi: 10.1016/S0140-6736(20)31953-X. Epub 2020 Sep 20. Lancet. 2020. PMID: 32966830 Clinical Trial.
Chemotherapy comprised of nab-paclitaxel at 125 mg/m(2) every week for 12 weeks followed by doxorubicin at 60 mg/m(2) and cyclophosphamide at 600 mg/m(2) every 2 weeks for 8 weeks, which was then followed by surgery. ...
Chemotherapy comprised of nab-paclitaxel at 125 mg/m(2) every week for 12 weeks followed by doxorubicin at 60 mg/m(2) and cycl …
Lymph node dissection in small peripheral lung cancer: Supplemental analysis of JCOG0802/WJOG4607L.
Maniwa T, Okami J, Miyoshi T, Wakabayashi M, Yoshioka H, Mimae T, Endo M, Hattori A, Nakagawa K, Isaka T, Isaka M, Kita R, Sekino Y, Mitome N, Aokage K, Saji H, Nakajima R, Okada M, Tsuboi M, Asamura H, Fukuda H, Watanabe SI; West Japan Oncology Group and Japan Clinical Oncology Group. Maniwa T, et al. Among authors: saji h. J Thorac Cardiovasc Surg. 2024 Sep;168(3):674-683.e1. doi: 10.1016/j.jtcvs.2023.11.023. Epub 2023 Nov 23. J Thorac Cardiovasc Surg. 2024. PMID: 38000629
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial.
Turner N, Dent RA, O'Shaughnessy J, Kim SB, Isakoff SJ, Barrios C, Saji S, Bondarenko I, Nowecki Z, Lian Q, Reilly SJ, Hinton H, Wongchenko MJ, Kovic B, Mani A, Oliveira M. Turner N, et al. Among authors: saji s. Breast Cancer Res Treat. 2022 Feb;191(3):565-576. doi: 10.1007/s10549-021-06450-x. Epub 2021 Dec 3. Breast Cancer Res Treat. 2022. PMID: 34860318 Free PMC article. Clinical Trial.
Patients were randomized 2:1 to ipatasertib (400 mg, days 1-21) or placebo, plus paclitaxel (80 mg/m(2), days 1, 8, 15), every 28 days until disease progression or unacceptable toxicity. ...
Patients were randomized 2:1 to ipatasertib (400 mg, days 1-21) or placebo, plus paclitaxel (80 mg/m(2), days 1, 8, 15), every 28 day …
The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition.
Terada M, Ito A, Kikawa Y, Koizumi K, Naito Y, Shimoi T, Ishihara M, Yamanaka T, Ozaki Y, Hara F, Nakamura R, Hattori M, Miyashita M, Kondo N, Yoshinami T, Takada M, Matsumoto K, Narui K, Sasada S, Iwamoto T, Hosoda M, Takano Y, Oba T, Sakai H, Murakami A, Higuchi T, Tsuchida J, Tanabe Y, Shigechi T, Tokuda E, Harao M, Kashiwagi S, Mase J, Watanabe J, Nagai SE, Yamauchi C, Yamamoto Y, Iwata H, Saji S, Toyama T. Terada M, et al. Among authors: saji s. Breast Cancer. 2023 Nov;30(6):872-884. doi: 10.1007/s12282-023-01505-x. Epub 2023 Oct 7. Breast Cancer. 2023. PMID: 37804479 Free PMC article.
Distinctive detection of insulinoma using [18F]FB(ePEG12)12-exendin-4 PET/CT.
Murakami T, Fujimoto H, Hamamatsu K, Yamauchi Y, Kodama Y, Fujita N, Fujikura J, Shimizu Y, Nakamoto Y, Kimura H, Saji H, Inagaki N. Murakami T, et al. Among authors: saji h. Sci Rep. 2021 Jul 22;11(1):15014. doi: 10.1038/s41598-021-94595-6. Sci Rep. 2021. PMID: 34294854 Free PMC article.
Cardiac Damage in Degenerative Mitral Regurgitation Treated With Transcatheter Mitral Edge-to-Edge Repair.
Sugiura A, Yamamoto M, Saji M, Asami M, Enta Y, Nakashima M, Shirai S, Izumo M, Mizuno S, Watanabe Y, Amaki M, Kodama K, Yamaguchi J, Nakajima Y, Naganuma T, Bota H, Ohno Y, Yamawaki M, Ueno H, Mizutani K, Adachi Y, Otsuka T, Kubo S, Nickenig G, Hayashida K; OCEAN-Mitral Investigators. Sugiura A, et al. Among authors: saji m. Circ Cardiovasc Interv. 2024 Jun;17(6):e013794. doi: 10.1161/CIRCINTERVENTIONS.123.013794. Epub 2024 Apr 17. Circ Cardiovasc Interv. 2024. PMID: 38629311 Free PMC article.
Alcohol consumption and breast cancer prognosis after breast cancer diagnosis: a systematic review and meta‑analysis of the Japanese Breast Cancer Society Clinical Practice Guideline, 2022 edition.
Nomura T, Kawai M, Fukuma Y, Koike Y, Ozaki S, Iwasaki M, Yamamoto S, Takamatsu K, Okamura H, Arai M, Ootani S, Iwata H, Saji S. Nomura T, et al. Among authors: saji s. Breast Cancer. 2023 Jul;30(4):519-530. doi: 10.1007/s12282-023-01455-4. Epub 2023 Apr 8. Breast Cancer. 2023. PMID: 37029889 Free PMC article.
Factors that influence women's enrolment and ongoing participation in a partially decentralised randomised controlled dermatology trial: a qualitative interview study with participants in the SAFA (Spironolactone for Adult Female Acne) trial.
Boxall C, Renz S, Eminton Z, Nuttall J, Saji A, Cluff C, Wilcox C, Muller I, Layton AM, Soulsby I, Santer M. Boxall C, et al. Among authors: saji a. Trials. 2023 Oct 12;24(1):661. doi: 10.1186/s13063-023-07630-4. Trials. 2023. PMID: 37821899 Free PMC article. Clinical Trial.
Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial.
Dent RA, Kim SB, Oliveira M, Barrios C, O'Shaughnessy J, Isakoff SJ, Saji S, Freitas-Junior R, Philco M, Bondarenko I, Lian Q, Bradley D, Hinton H, Wongchenko MJ, Reilly SJ, Turner N. Dent RA, et al. Among authors: saji s. Clin Cancer Res. 2024 Oct 1;30(19):4329-4338. doi: 10.1158/1078-0432.CCR-24-0465. Clin Cancer Res. 2024. PMID: 39058425 Free PMC article. Clinical Trial.
165 results